Royal Bank of Canada
ABBV icon

Royal Bank of Canada’s AbbVie ABBV Stock Holding History

Royal Bank of Canada’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.64B Sell
7,534,148
-355,721
-5% -$78.9M 0.29% 64
2025
Q4 		$1.8B Sell
7,889,869
-472,227
-6% -$108M 0.29% 60
2025
Q3 		$1.94B Sell
8,362,096
-904,371
-10% -$184M 0.32% 56
2025
Q2 		$1.72B Buy
9,266,467
+436,030
+5% +$81M 0.31% 60
2025
Q1 		$1.85B Buy
8,830,437
+109,897
+1% +$21.4M 0.39% 50
2024
Q4 		$1.55B Sell
8,720,540
-144,756
-2% -$26.6M 0.31% 63
2024
Q3 		$1.75B Buy
8,865,296
+238,597
+3% +$44.5M 0.36% 57
2024
Q2 		$1.48B Buy
8,626,699
+491,639
+6% +$81.4M 0.34% 65
2024
Q1 		$1.48B Sell
8,135,060
-627,994
-7% -$108M 0.34% 64
2023
Q4 		$1.36B Sell
8,763,054
-486,564
-5% -$70.9M 0.32% 66
2023
Q3 		$1.38B Buy
9,249,618
+92,234
+1% +$13.5M 0.37% 55
2023
Q2 		$1.23B Sell
9,157,384
-553,429
-6% -$81.2M 0.32% 68
2023
Q1 		$1.55B Sell
9,710,813
-65,354
-0.7% -$9.99M 0.44% 46
2022
Q4 		$1.58B Buy
9,776,167
+655,096
+7% +$100M 0.45% 45
2022
Q3 		$1.22B Sell
9,121,071
-383,387
-4% -$55M 0.39% 55
2022
Q2 		$1.46B Buy
9,504,458
+288,151
+3% +$44M 0.43% 44
2022
Q1 		$1.49B Sell
9,216,307
-1,190,762
-11% -$173M 0.37% 47
2021
Q4 		$1.41B Buy
10,407,069
+428,451
+4% +$50.6M 0.32% 61
2021
Q3 		$1.08B Buy
9,978,618
+44,549
+0.4% +$5.09M 0.28% 78
2021
Q2 		$1.12B Buy
9,934,069
+607,969
+7% +$68.5M 0.3% 71
2021
Q1 		$1.01B Sell
9,326,100
-1,764,682
-16% -$189M 0.29% 73
2020
Q4 		$1.19B Buy
11,090,782
+495,144
+5% +$47.6M 0.34% 59
2020
Q3 		$928M Sell
10,595,638
-69,228
-0.6% -$6.52M 0.33% 68
2020
Q2 		$1.05B Buy
10,664,866
+2,038,084
+24% +$179M 0.42% 48
2020
Q1 		$657M Buy
8,626,782
+98,691
+1% +$8.41M 0.32% 69
2019
Q4 		$755M Buy
8,528,091
+1,211,667
+17% +$101M 0.27% 77
2019
Q3 		$554M Buy
7,316,424
+1,412,109
+24% +$96.8M 0.22% 93
2019
Q2 		$429M Buy
5,904,315
+202,788
+4% +$15.9M 0.17% 116
2019
Q1 		$459M Buy
5,701,527
+236,860
+4% +$19.4M 0.2% 106
2018
Q4 		$504M Sell
5,464,667
-85,747
-2% -$7.54M 0.24% 84
2018
Q3 		$525M Sell
5,550,414
-216,136
-4% -$20.5M 0.22% 90
2018
Q2 		$534M Buy
5,766,550
+18,265
+0.3% +$1.78M 0.24% 89
2018
Q1 		$544M Sell
5,748,285
-511,929
-8% -$56.2M 0.24% 80
2017
Q4 		$605M Buy
6,260,214
+264,486
+4% +$24.9M 0.27% 78
2017
Q3 		$533M Buy
5,995,728
+290,088
+5% +$22.1M 0.26% 77
2017
Q2 		$414M Buy
5,705,640
+200,356
+4% +$13.5M 0.21% 89
2017
Q1 		$359M Buy
5,505,284
+461,681
+9% +$29M 0.19% 96
2016
Q4 		$316M Sell
5,043,603
-1,116,673
-18% -$68.2M 0.17% 99
2016
Q3 		$389M Buy
6,160,276
+326,726
+6% +$21.2M 0.22% 79
2016
Q2 		$361M Buy
5,833,550
+657,317
+13% +$40.1M 0.21% 84
2016
Q1 		$296M Buy
5,176,233
+717,136
+16% +$40M 0.18% 90
2015
Q4 		$264M Buy
4,459,097
+129,012
+3% +$7.43M 0.17% 101
2015
Q3 		$236M Sell
4,330,085
-69,322
-2% -$4.51M 0.18% 94
2015
Q2 		$296M Buy
4,399,407
+1,400,241
+47% +$91.4M 0.2% 77
2015
Q1 		$176M Sell
2,999,166
-949,814
-24% -$57.4M 0.12% 127
2014
Q4 		$258M Sell
3,948,980
-224,189
-5% -$14.1M 0.17% 90
2014
Q3 		$241M Sell
4,173,169
-353,450
-8% -$19.6M 0.16% 93
2014
Q2 		$255M Buy
4,526,619
+815,636
+22% +$42.8M 0.17% 86
2014
Q1 		$191M Sell
3,710,983
-346,002
-9% -$17.5M 0.14% 100
2013
Q4 		$214M Buy
4,056,985
+1,153,875
+40% +$56.7M 0.15% 103
2013
Q3 		$130M Sell
2,903,110
-256,087
-8% -$11.4M 0.1% 148
2013
Q2 		$131M Buy
+3,159,197
New +$138M 0.11% 125

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Royal Bank of Canada's ABBV Position: Q1 2026 in Review

Royal Bank of Canada reduced its AbbVie (ABBV) stake by 4.5% in Q1 2026, selling an estimated $78.9M and leaving 7,534,148 shares worth $1.64B. The position accounts for 0.29% of the portfolio, ranked #64.

Royal Bank of Canada first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.94B in Q3 2025. 4,081 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Royal Bank of Canada held 7,534,148 shares of AbbVie worth $1.64B as of Q1 2026.
  • Royal Bank of Canada sold 355,721 AbbVie shares in Q1 2026, an estimated $78.9M.
  • AbbVie made up 0.29% of Royal Bank of Canada's portfolio in Q1 2026, its #64 holding.
  • Royal Bank of Canada first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's AbbVie position peaked at $1.94B in Q3 2025.
  • 4,081 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.